FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898133719> ?p ?o ?g. }

• W2898133719 endingPage "1424" @default.
• W2898133719 startingPage "1424" @default.
• W2898133719 abstract "Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Despite standard prophylactic measures, there is a wide variability in the severity of this complication, which could be associated with both genetic and environmental factors.To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.This case series study was conducted in 12 university referral hospitals in Spain from September 17, 2014, to February 6, 2015. One hundred twenty-five patients with a confirmed diagnosis of CTCL who had received bexarotene therapy for at least 3 months were enrolled. Nine patients were excluded owing to missing analytic triglyceride level data, leaving a study group of 116 patients. Data on demographic and cardiovascular risk factor were collected, and a complete blood analysis, including lipid profile and genetic analysis from a saliva sample, was performed.Primary outcomes were the maximal triglyceride levels reported in association with the minor alleles of the polymorphisms studied.Among 116 patients, the mean (SD) age was 61.2 (14.7) years, 69 (59.5%) were men, and 85 (73.2%) had mycosis fungoides, the most prevalent form of CTCL. During bexarotene therapy, 96 patients (82.7%) experienced hypertriglyceridemia, which was severe or extreme in 8 of these patients (8.3%). Patients who carried minor alleles of the polymorphisms did not show significant differences in baseline triglyceride concentrations. After bexarotene treatment, carriers of at least 1 of the 2 minor alleles of APOA5 c.-1131T>C and APOC3 c.*40C>G showed lower levels of triglycerides than noncarriers (mean [SD], 241.59 [169.91] vs 330.97 [169.03] mg/dL, respectively; P = .02).These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile." @default.
• W2898133719 created "2018-11-02" @default.
• W2898133719 creator A5009226979 @default.
• W2898133719 creator A5026292617 @default.
• W2898133719 creator A5040040159 @default.
• W2898133719 creator A5040812031 @default.
• W2898133719 creator A5041803353 @default.
• W2898133719 creator A5046082972 @default.
• W2898133719 creator A5048199617 @default.
• W2898133719 creator A5050203761 @default.
• W2898133719 creator A5052268220 @default.
• W2898133719 creator A5052750968 @default.
• W2898133719 creator A5054096721 @default.
• W2898133719 creator A5054125403 @default.
• W2898133719 creator A5069932324 @default.
• W2898133719 creator A5078120465 @default.
• W2898133719 creator A5081538785 @default.
• W2898133719 creator A5090263713 @default.
• W2898133719 date "2018-12-01" @default.
• W2898133719 modified "2023-10-18" @default.
• W2898133719 title "Association of <i>APOA5</i> and <i>APOC3</i> Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene" @default.
• W2898133719 cites W1499351797 @default.
• W2898133719 cites W1554704299 @default.
• W2898133719 cites W1966070073 @default.
• W2898133719 cites W1979928832 @default.
• W2898133719 cites W2032379578 @default.
• W2898133719 cites W2047417330 @default.
• W2898133719 cites W2061215000 @default.
• W2898133719 cites W2071436370 @default.
• W2898133719 cites W2080036080 @default.
• W2898133719 cites W2082948426 @default.
• W2898133719 cites W2086499692 @default.
• W2898133719 cites W2096850086 @default.
• W2898133719 cites W2108022321 @default.
• W2898133719 cites W2112581524 @default.
• W2898133719 cites W2113349793 @default.
• W2898133719 cites W2113481191 @default.
• W2898133719 cites W2117252673 @default.
• W2898133719 cites W2117326539 @default.
• W2898133719 cites W2117903085 @default.
• W2898133719 cites W2136054920 @default.
• W2898133719 cites W2142850613 @default.
• W2898133719 cites W2162588312 @default.
• W2898133719 cites W2165441215 @default.
• W2898133719 cites W2342031079 @default.
• W2898133719 cites W2590982770 @default.
• W2898133719 cites W2607031541 @default.
• W2898133719 cites W2623658063 @default.
• W2898133719 cites W4232245000 @default.
• W2898133719 cites W4233327123 @default.
• W2898133719 cites W4237937334 @default.
• W2898133719 cites W4238251256 @default.
• W2898133719 cites W4241201978 @default.
• W2898133719 cites W4242683887 @default.
• W2898133719 cites W4246202180 @default.
• W2898133719 cites W4292528167 @default.
• W2898133719 doi "https://doi.org/10.1001/jamadermatol.2018.3679" @default.
• W2898133719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6583311" @default.
• W2898133719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30422238" @default.
• W2898133719 hasPublicationYear "2018" @default.
• W2898133719 type Work @default.
• W2898133719 sameAs 2898133719 @default.
• W2898133719 citedByCount "7" @default.
• W2898133719 countsByYear W28981337192019 @default.
• W2898133719 countsByYear W28981337192020 @default.
• W2898133719 countsByYear W28981337192021 @default.
• W2898133719 countsByYear W28981337192023 @default.
• W2898133719 crossrefType "journal-article" @default.
• W2898133719 hasAuthorship W2898133719A5009226979 @default.
• W2898133719 hasAuthorship W2898133719A5026292617 @default.
• W2898133719 hasAuthorship W2898133719A5040040159 @default.
• W2898133719 hasAuthorship W2898133719A5040812031 @default.
• W2898133719 hasAuthorship W2898133719A5041803353 @default.
• W2898133719 hasAuthorship W2898133719A5046082972 @default.
• W2898133719 hasAuthorship W2898133719A5048199617 @default.
• W2898133719 hasAuthorship W2898133719A5050203761 @default.
• W2898133719 hasAuthorship W2898133719A5052268220 @default.
• W2898133719 hasAuthorship W2898133719A5052750968 @default.
• W2898133719 hasAuthorship W2898133719A5054096721 @default.
• W2898133719 hasAuthorship W2898133719A5054125403 @default.
• W2898133719 hasAuthorship W2898133719A5069932324 @default.
• W2898133719 hasAuthorship W2898133719A5078120465 @default.
• W2898133719 hasAuthorship W2898133719A5081538785 @default.
• W2898133719 hasAuthorship W2898133719A5090263713 @default.
• W2898133719 hasBestOaLocation W28981337191 @default.
• W2898133719 hasConcept C104317684 @default.
• W2898133719 hasConcept C126322002 @default.
• W2898133719 hasConcept C156957248 @default.
• W2898133719 hasConcept C2776919658 @default.
• W2898133719 hasConcept C2777756187 @default.
• W2898133719 hasConcept C2778163477 @default.
• W2898133719 hasConcept C2778820923 @default.
• W2898133719 hasConcept C2778913445 @default.
• W2898133719 hasConcept C2779338263 @default.
• W2898133719 hasConcept C54355233 @default.
• W2898133719 hasConcept C63932345 @default.
• W2898133719 hasConcept C71924100 @default.
• W2898133719 hasConcept C86339819 @default.

• next